T2-high asthma, classified by sputum mRNA expression of IL4, IL5, and IL13, is characterized by eosinophilia and severe phenotype [Elektronski vir]Rijavec, Matija ...Asthma is a common chronic disease, with different underlying inflammatory mechanisms. Identification of asthma endotypes, which reflect a variable response to different treatments, is important for ... more precise asthma management. T2 asthma is characterized by airway inflammation driven by T2 cytokines including interleukins IL-4, IL-5, and IL-13. This study aimed to determine whether induced sputum samples can be used for gene expression profiling of T2-high asthma classified by IL4, IL5, and IL13 expression. Induced sputum samples were obtained from 44 subjects, among them 36 asthmatic patients and eight controls, and mRNA expression levels of IL4, IL5, and IL13 were quantified by RT-qPCR. Overall, gene expression levels of IL4, IL5, and IL13 were significantly increased in asthmatic patients' samples compared to controls and there was a high positive correlation between expressions of all three genes. T2 gene mean was calculated by combining the expression levels of all three genes (IL4, IL5, and IL13) and according to T2 gene mean expression in controls, we set a T2-high/T2-low cutoff value. Twenty-four (67%) asthmatic patients had T2-high endotype and those patients had significantly higher eosinophil blood and sputum counts. Furthermore, T2-high endotype was characterized as a more severe, difficult-to-treat asthma, and often uncontrolled despite the use of inhaled and/or oral corticosteroids. Therefore, the majority of those patients (15 [63%] of 24) needed adjunct biological therapy to control their asthma symptoms/exacerbations. In conclusion, we found that interleukins IL4, IL5, and IL13 transcripts could be effectively detected in sputum from asthmatic patients. Implementation of T2 gene mean can be used as sputum molecular biomarker to categorize patients into T2-high endotype, characterized by eosinophilia and severe, difficult-to-treat asthma, and often with a need for biological treatment.Vir: Life [Elektronski vir]. - ISSN 2075-1729 (Vol. 11, iss. 2, Feb. 2021, str. 1-10)Vrsta gradiva - e-članek ; neleposlovje za odrasleLeto - 2021Jezik - angleškiCOBISS.SI-ID - 49321987
Asthma | Gene expression | Interleukin-4 | Interleukin-5 | Interleukin-13 | Astma | Gensko izražanje | Interlevkin-4 | Interlevkin-5 | Interlevkin-13 | težka astma | endotip | IL-4 | IL-5 | IL-13 | biološko zdravljenje | severe asthma | endotype | biologic treatment
Vnos na polico
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Baze podatkov, v katerih je revija indeksirana
|Ime baze podatkov||Področje||Leto|
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Gesla v Splošnem geslovniku COBISS
Prosimo, počakajte trenutek.